EPRX vs IRWD vs PTGX vs PRGO vs JNJ

For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 4.

3% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Ironwood Pharmaceuticals, Inc. (IRWD) offers the better valuation at 28. 1x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Eupraxia Pharmaceuticals Inc. (EPRX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Ironwood Pharmaceuticals, Inc.

(IRWD) is the cheapest at 28. 1x versus Johnson & Johnson at 38. 2x. On forward P/E, Ironwood Pharmaceuticals, Inc. is actually cheaper at 3. 1x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +251. 2%, compared to -61. 6% for Ironwood Pharmaceuticals, Inc. (IRWD). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Ironwood Pharmaceuticals, Inc. 's 2. 62β — meaning IRWD is approximately 5736% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Eupraxia Pharmaceuticals Inc. (EPRX) carries a lower debt/equity ratio of 0% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 4.

3% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Eupraxia Pharmaceuticals Inc. grew EPS -38. 2% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Ironwood Pharmaceuticals, Inc.

(IRWD) trades at 3. 1x forward P/E versus 25. 8x for Protagonist Therapeutics, Inc. — 22. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield), JNJ (2. 2% yield) pay a dividend. EPRX, IRWD, PTGX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +131. 3%, IRWD: -58. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EPRX is a small-cap quality compounder stock; IRWD is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; JNJ is a large-cap quality compounder stock. PRGO, JNJ pay a dividend while EPRX, IRWD, PTGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.